You are here

Memory Loss

 

A Phase 2A Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of 50 mg and 100 mg of SUVN-502 in Subjects with Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride

PI:  Tom Ala, MD

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease - BN29552

PI:  Tom Ala, MD

A Phase 2 Multiple Dose, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease

PI:  Tom Ala, MD

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease

PI:  Tom Ala, MD

     

A PhaseIII, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease - WN29922

PI:  Tom Ala, MD

Caregiver Characteristics That May Predict When Patients With Alzheimer's Disease Are Placed in Long-term Care Facilities

PI:  Tom Ala, MD

Illinois Department on Aging

Alzheimer's Disease Initiative - Specialized Supportive Services

PI:  Tom Ala, MD